iX Biopharma (SGX:42C) Equity-to-Asset

: 0.42 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. iX Biopharma's Total Stockholders Equity for the quarter that ended in Dec. 2023 was S$7.66 Mil. iX Biopharma's Total Assets for the quarter that ended in Dec. 2023 was S$18.31 Mil. Therefore, iX Biopharma's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.42.

The historical rank and industry rank for iX Biopharma's Equity-to-Asset or its related term are showing as below:

SGX:42C' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.42 Med: 0.69 Max: 0.88
Current: 0.42

During the past 10 years, the highest Equity to Asset Ratio of iX Biopharma was 0.88. The lowest was 0.42. And the median was 0.69.

SGX:42C's Equity-to-Asset is ranked worse than
69.89% of 1086 companies
in the Drug Manufacturers industry
Industry Median: 0.59 vs SGX:42C: 0.42

iX Biopharma Equity-to-Asset Historical Data

The historical data trend for iX Biopharma's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iX Biopharma Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Equity-to-Asset

Get a 7-Day Free Trial

0.77

0.60

0.62

0.69

0.64

iX Biopharma Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Equity-to-Asset	Get a 7-Day Free Trial															0.74	0.69	0.67	0.64	0.42

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, iX Biopharma's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

iX Biopharma Equity-to-Asset Distribution

For the Drug Manufacturers industry and Healthcare sector, iX Biopharma's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where iX Biopharma's Equity-to-Asset falls into.

iX Biopharma Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

iX Biopharma's Equity to Asset Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Equity to Asset (A: Jun. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	15.852	/	24.928
	=	0.64

iX Biopharma's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	7.657	/	18.309
	=	0.42

iX Biopharma (SGX:42C) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

iX Biopharma Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of iX Biopharma's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

iX Biopharma (SGX:42C) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » iX Biopharma Ltd (SGX:42C) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Kim Seng Promenade, No. 14-01, Great World City East Lobby, Singapore, SGP, 237994

Website

https://www.ixbiopharma.com

iX Biopharma Ltd is a Singapore-based specialty pharmaceutical and nutraceutical company focused on the development, manufacture, and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. Its products under development are Wafermine and BnoX for pain management, Wafesil for erectile dysfunction, WafeRest for improved sleep quality, and others. Its business segments are Specialty Pharmaceutical and Nutraceutical business segments. The firm's business segments operate in United States of America, Singapore, Australia, and China, of which the majority of the revenue comes from the United States of America. The company generates the majority of its revenue from the sale of specialty pharmaceutical products.

iX Biopharma (SGX:42C) Headlines

No Headlines